Aqupla (nedaplatin) / Simcere - LARVOL DELTA

Prolonged Progression-Free Survival in a Patient with Highly Pretreated Recurrent Ovarian Cancer after Developing Multisystem Immune-Related Adverse Events: A Case Report and Literature Review. (PubMed, Case Rep Oncol) - "Between 2013 and 2021, she underwent palliative chemotherapy comprising paclitaxel liposomes, cisplatin/nedaplatin, S-1/raltitrexed, irinotecan, doxorubicin, vinorebine, toripalimab, apatinib, gemcitabine, oxaliplatin, and capecitabine, as well as two debulking surgeries. From November 2021, she received six cycles of tislelizumab (a PD-1 inhibitor), paclitaxel (albumin-bound), and carboplatin, to which a partial response was observed according to the Response Evaluation Criteria in Solid Tumors. From May 2022, the patient was switched to maintenance therapy with tislelizumab plus olaparib...We report a case involving a patient with highly pretreated recurrent ovarian cancer who exhibited prolonged PFS after developing three irAEs. The distinctly prolonged PFS observed, along with the reviewed literature, suggests that irAEs may be correlated with improved survival in ovarian cancer."

Adverse events • IO biomarker • Journal • Tumor mutational burden • Endocrine Disorders • Gynecology • Microsatellite Instability • Nephrology • Obstetrics • Oncology • Ovarian Cancer • Pneumonia • Renal Disease • Solid Tumor • MSI • TMB

Immune checkpoint inhibitors combined with targeted therapy for long-term survival in advanced pulmonary squamous cell carcinoma after first-line failure: A case report and literature review. (PubMed, Medicine (Baltimore)) - "This case underscores the potential efficacy of combining immune checkpoint inhibitors with small-molecule multi-targeted tyrosine kinase inhibitors in treating advanced SCC of the lung after progression on first-line therapy. The complementary mechanisms of immune modulation and tumor microenvironment normalization may offer an effective strategy for addressing immune resistance in SCC."

Checkpoint inhibition • IO biomarker • Journal • Cardiovascular • Cough • Endocrine Disorders • Hypertension • Immune Modulation • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • PD-L1

Long-term immune checkpoint inhibitor therapy in a patient with metastatic nasopharyngeal carcinoma: a case report. (PubMed, Front Immunol) - "Current pivotal trials predominantly advocate for a fixed two-year regimen of immune checkpoint inhibitors (ICIs), exemplified by pembrolizumab and toripalimab, as first-line therapy for patients with advanced malignancies. Alternatively, for specific ICIs, including nivolumab, camrelizumab, and tislelizumab, continuous administration until disease progression has emerged as a favored approach...The patient completed two cycles of induction chemotherapy with liposomal paclitaxel and nedaplatin, followed by platinum-based concurrent chemoradiotherapy, resulting in a progression-free survival (PFS) of 23.6 months...EBV DNA levels could serve as an informative marker to predict the necessity of therapy discontinuation during immunotherapy maintenance. Notably, a post-discontinuation ICI rechallenge can still yield favorable outcomes potentially accredited to immune memory."

Checkpoint inhibition • IO biomarker • Journal • Epstein-Barr Virus Infections • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Pain • Solid Tumor

Real-world data of docetaxel-induced liver injury among hospitalized patients in Wuhan, China: A retrospective analysis. (PubMed, Medicine (Baltimore)) - "Among these therapeutic combination regimens, docetaxel plus epirubicin, docetaxel plus nedaplatin, and docetaxel plus capecitabine could significantly increase the occurrence of docetaxel-induced liver injury during hospitalization respectively, while docetaxel plus cyclophosphamide regime might be safer. Therefore, for patients with these risk factors, it might be advisable to actively consider optimum management to reduce the occurrence of docetaxel-induced liver injury during hospitalization, particularly hepatic function test."

Journal • Observational data • Real-world evidence • Retrospective data • Diabetes • Hepatitis B • Hepatology • Infectious Disease • Liver Failure • Metabolic Disorders • Oncology • Ovarian Cancer • Solid Tumor

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma (clinicaltrials.gov) - P2 | N=26 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xiamen University

New P2 trial • Esophageal Cancer • Oncology • Squamous Cell Carcinoma

Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study. (ASCO 2025) - P1/2 | "The combination of fruquintinib, camrelizumab, paclitaxel liposome, and nedaplatin demonstrated significant efficacy and manageable toxicity profile as a first-line treatment for advanced ESCC, suggesting a potential new treatment strategy."

Clinical • Combination therapy • Metastases • P2 data • Anemia • Cardiovascular • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Hematological Disorders • Hypertension • Leukopenia • Mucositis • Neutropenia • Oncology • Pain • Squamous Cell Carcinoma • Stomatitis

A phase II study of prophylactic thrombopoietin combined with magnetic resonance guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy and concurrent chemotherapy for thoracic esophageal cancer. (ASCO 2025) - P2 | "The treatment regimen consisted of BM-sparing intensity modulated radiotherapy (BMS-IMRT) (≥45Gy) and concurrent chemotherapy (five cycles of weekly intravenous paclitaxel [50 mg/m²] and cisplatin/nedaplatin [25 mg/m²], or two cycles of intravenous paclitaxel [135-175 mg/m²] and cisplatin [80 mg/m²]), and rhTPO (15000U ih. Techniques to limit low dose radiation to active BM and prophylactic rhTPO could reduce thrombocytopenia in thoracic EC patients treated with CRT."

P2 data • Anemia • Esophageal Cancer • Leukopenia • Oncology • Thrombocytopenia

Camrelizumab combined with paclitaxel and nedaplatin as conversion therapy for locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm exploratory study. (ASCO 2025) - P2 | "The combination of camrelizumab, paclitaxel, and nedaplatin demonstrates promising efficacy and manageable adverse effects as a conversion therapy, enhancing surgical resectability and survival outcomes without delaying surgery. Table 1. Survival outcomes."

Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research. (ASCO 2025) - P=N/A | "The ESPRIT study indicates that camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy is well tolerated, effectively reducing tumor size and stage. This regimen also demonstrates favorable outcomes in overall survival and significantly extends disease-free survival. These promising results support the continued investigation of this treatment approach."

Clinical • IO biomarker • Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • PD-L1

A retrospective pilot study of neoadjuvant chemotherapy combined with immunotherapy in the treatment of thoracic esophageal squamous cell carcinoma with cervical lymph node metastasis. (ASCO 2025) - "19 patients received camrelizumab, nab-paclitaxel, and S-1 regimen and 1 received tislelizumab, nab-paclitaxel and nedaplatin regimen. With manageable safety profiles, high pathological response rates and enhanced survival rates, neoadjuvant CIT shows significant potential for improving clinical outcomes in ESCC and CLNM. Further prospective trials are needed to fully evaluate the effectiveness and safety of this treatment strategy for these patients. Baseline Characteristics of the Patients"

Retrospective data • Anemia • Cervical Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Hematological Disorders • Infectious Disease • Oncology • Pneumonia • Respiratory Diseases • Squamous Cell Carcinoma

Safety and efficacy analysis of neoadjuvant radiotherapy combined with concurrent paclitaxel plus nedaplatin versus other platinum-based chemotherapy for thoracic segmental esophageal squamous cell carcinoma. (PubMed, Front Oncol) - "A total of 212 patients were enrolled in this retrospective cohort study, including 79 who received NDP and 133 who received OPB (82 were treated with cisplatin, 20 with carboplatin, 19 with lobaplatin, and 12 with oxaliplatin) agents. The Kaplan-Meier curves for overall survival (OS) and progression-free survival (PFS) showed similar results for both groups. The safety profile of nedaplatin may be superior to those of other platinum-based agents in terms of acute radiotherapy toxicity and postoperative side effects; however, there was no difference in the efficacy between the two groups regarding short-term prognostic tumor regression grades or long-term OS and PFS."

Journal • Anorexia • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Hematological Malignancies • Leukemia • Oncology • Pneumonia • Squamous Cell Carcinoma

QuEChERS and UPLC-MS/MS-Based Quantification of Human Plasma of Eight Nucleoside Reverse Transcriptase Inhibitors and Platinum Anticancer Drugs for Hepatocellular Carcinoma. (PubMed, Molecules) - "The target analytes-lamivudine, telbivudine, emtricitabine, entecavir, tenofovir, nedaplatin, oxaliplatin, and adefovir dipivoxil-exhibited strong linearity within the 10-1000 ng/mL and 1-100 ng/mL ranges, showing correlations (r2) ≥ 0.9962. Overall, this analytical approach can be used to detect the combination of eight NRTIs and platinum-based drugs in human plasma. This method enables plasma drug-level monitoring in real time, with applications for individualized treatment approaches."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

A comparison of the survival outcome of paclitaxel liposome-based chemoradiotherapy with or without rhEndostatin for unresectable esophageal squamous cell carcinoma: a retrospective study. (PubMed, Discov Oncol) - "The addition of rhEndostatin to paclitaxel liposome-based dCRT may improve clinical outcomes for patients with unresectable ESCC while maintaining manageable toxicities. However, further prospective randomized controlled studies are necessary to confirm the survival benefits of this treatment strategy."

Journal • Retrospective data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Squamous Cell Carcinoma • Thrombocytopenia

Effects of nedaplatin combined with paclitaxel liposomes or docetaxel on survival rate and biomarkers in patients with recurrent ovarian cancer. (PubMed, Am J Transl Res) - "The combination of nedaplatin with paclitaxel liposomes or docetaxel demonstrated comparable efficacy in ROC patients, effectively reducing tumor and inflammatory markers without increasing adverse reactions. Importantly, the combination of nedaplatin and docetaxel significantly improved PFS."

Biomarker • Journal • Oncology • Ovarian Cancer • Solid Tumor • IL6 • TNFA

Safety and efficacy analysis of neoadjuvant radiotherapy combined with concurrent paclitaxel plus nedaplatin versus other platinum-based chemotherapy for thoracic segmental esophageal squamous cell carcinoma (Frontiers) - "A total of 212 patients were enrolled in this retrospective cohort study, including 79 who received NDP and 133 who received OPB (82 were treated with cisplatin, 20 with carboplatin, 19 with lobaplatin, and 12 with oxaliplatin) agents. The incidences of grade 3–4 acute radiotherapy-associated esophagitis, pneumonitis, and leukemia were significantly lower in the NDP group than in the OPB group (p = 0.02, p < 0.001, and p = 0.002, respectively). All grades of acute gastrointestinal reactions, including nausea, vomiting, anorexia, and diarrhea, were significantly more frequent in the OPB group than in the NPD group (p < 0.001, p = 0.032, p < 0.001, and p = 0.002, respectively). The Kaplan–Meier curves for overall survival (OS) and progression-free survival (PFS) showed similar results for both groups."

Retrospective data • Esophageal Squamous Cell Carcinoma

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=86 | Not yet recruiting | Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd.

New P1/2 trial • Solid Tumor

Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial. (PubMed, EClinicalMedicine) - P2 | "Patients received neoadjuvant therapy comprised of albumin-bound paclitaxel, nedaplatin and toripalimab every 3 weeks, for 2 cycles, followed by CCRT (total dose 60Gy in cohort A, 50Gy in cohort B, combined with oral capecitabine). Further investigation is warranted. None."

Journal • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Pneumonia • Squamous Cell Carcinoma

Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score matched analysis. (PubMed, Clin Transl Radiat Oncol) - "All patients underwent intensity-modulated radiation therapy (IMRT), and CCRT group received two cycles of concurrent docetaxel and nedaplatin. Upcoming results from randomized studies are anticipated to shed more light on this debated issue. CCRT should be avoided outside of clinical trials."

Journal • Adenoid Cystic Carcinoma • Head and Neck Cancer • Oncology

A case of camrelizumab-induced anaphylaxis and successful rechallenge: a case report and literature review. (PubMed, Front Oncol) - "He underwent multiple cycles of therapy, tolerating camrelizumab, nab-paclitaxel, and nedaplatin (200 mg of camrelizumab every 3 weeks) without adverse reactions in the first four cycles...The camrelizumab infusion was immediately halted, and the patient was treated with intravenous dexamethasone (10 mg) combined with intramuscular diphenhydramine, calcium gluconate, and 500 ml of normal saline; his blood pressure gradually increased to 110/80 mmHg within 10 minutes, and pruritic erythematous macules appeared on his skin, particularly on the upper limbs...The patient did not report significant discomfort. Although acute allergic reactions are relatively rare among immune-related adverse events, due to the widespread clinical application of camrelizumab, its potential for allergic reactions should be given high priority."

Journal • Allergy • Hypotension • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

SMARCA4-deficient non-small cell lung cancer with metastasis to the sigmoid colon: a case report. (PubMed, World J Surg Oncol) - "This case represents the first reported instance of SMARCA4-dNSCLC with metastasis to the sigmoid colon. The atypical clinical and radiological features of this condition pose significant diagnostic challenges, particularly in differentiating metastatic lesions from primary colonic tumors. This case underscores the significance of recognizing rare metastatic patterns in SMARCA4-dNSCLC, enriching the literature on its diverse manifestations and providing a critical reference for clinicians in diagnosing and managing SMARCA4-dNSCLC with sigmoid colon metastasis."

Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Otorhinolaryngology • Solid Tumor • SMARCA4 • SMARCD3

Safety and Efficacy of Unresectable Malignant Cardiac Tumors Treated with Concurrent Chemoradiation Therapy Using a 1.5T MR-Linac (GASTO-1078). (PubMed, Int J Radiat Oncol Biol Phys) - "Split-course hypo-CCRT on MR-Linac for malignant cardiac tumors was feasible, generally well-tolerated, and showed promising oncologic as well as patient-reported outcomes in this small prospective cohort. Further study is warranted for the long-term effects."

Journal • Oncology

Efficacy and safety of nanoparticle albumin-bound paclitaxel plus cisplatin or nedaplatin plus tegafur/gimeracil/oteracil as induction chemotherapy regimen for hypopharyngeal cancer. (PubMed, Front Oncol) - "The combination of docetaxel, cisplatin, and 5-fluorouracil as a standard induction chemotherapy regimen allows enhanced laryngeal preservation after surgery. No grade 4/5 treatment-emergent adverse events were observed. The combination of nab-paclitaxel, cisplatin/nedaplatin, and tegafur/gimeracil/oteracil is a safe induction chemotherapy for treating hypopharyngeal cancer."

Journal • Alopecia • Head and Neck Cancer • Hematological Disorders • Hypopharyngeal Cancer • Immunology • Leukopenia • Oncology • Solid Tumor

Two Cases of Advanced Esophageal Cancer with Pathological Complete Response after Neoadjuvant Chemotherapy with 5-Fluorouracil, Docetaxel, and Nedaplatin(UDON) (PubMed, Gan To Kagaku Ryoho) - "We report 2 pathological complete response (pCR) cases of neoadjuvant UDON(5-fluorouracil, docetaxel, and nedaplatin)therapy without any adverse events in advanced esophageal squamous cell carcinoma. UDON therapy, which is similar to DCF(docetaxel, cisplatin, and 5-FU)therapy, comprises divided doses of docetaxel and nedaplatin, which minimizes adverse effects on the bone marrow, heart, and kidneys. UDON therapy may be a safe and effective regimen and a reasonable and recommended choice for older and high-risk patients with advanced esophageal cancer."

Journal • Cardiovascular • Coronary Artery Disease • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Heart Failure • Oncology • Squamous Cell Carcinoma

Usefulness of Preoperative Clinical Pathway for Esophageal Cancer-Preoperative Chemotherapy(UDON), Minimally Invasive Mediastinoscopic Esophagectomy, and Night Home Enteral Nutrition Therapy (PubMed, Gan To Kagaku Ryoho) - "A clinical pathway including UDON therapy, minimally invasive mediastinoscopic esophagectomy with nerve integrity monitoring, and postoperative enteral nutritional therapy can provide multidisciplinary treatment without worsening nutritional status and ADL."

Journal • Retrospective data • Esophageal Cancer • Oncology

Cilostazol protective effect on nedaplatin-induced genotoxicity in cultured human lymphocytes. (PubMed, Toxicol Rep) - "Pretreatment with cilostazol partially debilitated the nedaplatin-induced changes in MI but not PI. Cilostazol ameliorated the genotoxicity of nedaplatin in cultured human lymphocytes."

Journal • Oncology